최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0834828 (2017-12-07) |
등록번호 | US-10159742 (2018-12-25) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 623 |
Fragmented polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and sy
Fragmented polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.
1. A method comprising administering a hydrogel composition to a subject, the hydrogel composition comprising an acetylated polysaccharide, a multifunctional, multi-armed polyethylene glycol polymer and a multifunctional, multi-armed crosslinker of polyethylene glycol, wherein: the acetylated polysa
1. A method comprising administering a hydrogel composition to a subject, the hydrogel composition comprising an acetylated polysaccharide, a multifunctional, multi-armed polyethylene glycol polymer and a multifunctional, multi-armed crosslinker of polyethylene glycol, wherein: the acetylated polysaccharide or derivative thereof has a molecular weight of 1000 Dalton to 80,300 Dalton, a degree of deacetylation of 70% to 99%, and at least two nucleophilic groups and is directly covalently bonded to the multifunctional, multi-armed polyethylene glycol polymer and directly covalently bonded to the multifunctional, multi-armed crosslinker of polyethylene glycol;the multifunctional, multi-armed polyethylene glycol polymer has a molecular weight of 5,000 Dalton to 30,000 Dalton, and comprises at least two nucleophilic groups and is directly covalently bonded to the acetylated polysaccharide or derivative thereof and is directly covalently bonded to the multifunctional, multi-armed crosslinker of polyethylene glycol; andthe multifunctional, multi-armed crosslinker of polyethylene glycol has a molecular weight of 5,000 Dalton to 30,000 Dalton, and comprises at least two electrophilic groups and is directly covalently bonded to the acetylated polysaccharide or derivative thereof and is directly covalently bonded to the multifunctional, multi-armed polyethylene glycol polymer,wherein the acetylated polysaccharide or derivative thereof does not act as a cross-linking agent in the hydrogel. 2. The method according to claim 1, wherein administering comprises positioning the hydrogel composition over at least a portion of a wound. 3. The method according to claim 2, wherein positioning the hydrogel composition is sufficient to reduce bleeding from the wound. 4. The method according to claim 2, wherein administering comprises positioning the hydrogel composition in a void in a tissue of the subject. 5. The method according to claim 4, wherein positioning of the hydrogel composition is sufficient to reduce leakage of a fluid across a suture line, an anastomoses or incision. 6. The method according to claim 4, wherein positioning of the hydrogel composition is sufficient to close vasculature or an aneurysm. 7. The method according to claim 1, wherein the hydrogel composition is applied to a medical implant and the method comprises contacting the medical implant to a tissue of the subject. 8. The method according to claim 7, wherein a recess, void or lumen of the medical implant is coated or filled with the hydrogel composition. 9. The method according to claim 1, wherein the hydrogel composition comprises hydrogel fragments. 10. The method according to claim 9, wherein the hydrogel fragments are selected from the group consisting of a dry powder, lyophilized, milled fragments, pulverized fragments, crushed fragments and grinded fragments. 11. The method according to claim 1, wherein the hydrogel composition further comprises a biologically active agent. 12. The method according to claim 11, wherein the biologically active agent is a steroid. 13. The method according to claim 12, wherein the steroid is mometasone furoate or triamcinolone. 14. The method according to claim 12, wherein the biologically active agent is an antibiotic. 15. The method according to claim 14, wherein the antibiotic is gentamicin. 16. The method according to claim 11, wherein the biologically active agent is a plasma protein, an enzyme, an antiseptic agent, an antineoplastic agent, an antifungal agent, an antiviral agent, an anti-inflammatory agent, a growth factor, an anesthetic, a cell suspension, a cytotoxin, a cell proliferation inhibitor, a biomimetic, an analgesic, a chemotherapeutic, a vasoconstrictor, a vasodilator, a cholesterol-lowering agent, a procoagulant, a selective serotonin reuptake inhibitor, a bone morphogenic protein, a growth factor, or a growth factor analog. 17. The method according to claim 1, wherein the polysaccharide or derivative thereof is a chitin, chitosan, or derivative thereof. 18. The method according to claim 1, wherein the hydrogel composition further comprises one or more of a thickening agent, a foaming agent, a visualization agent, or a radiopaque agent. 19. The method according to claim 1, wherein the hydrogel composition is administered to the subject with a syringe. 20. The method according to claim 19, wherein the syringe contains fragments of the hydrogel composition in a buffer solution.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.